1.74
-3.33%
Close of 9 Nov 2026, in SEK
Search any instrument
Reference data, closing prices and charts across 45,000 companies, plus crypto, commodities and currencies.
About Clinical Laserthermia Systems
Its shares trade on Nasdaq Stockholm under the ticker CLS B.ST. It has been listed since 16 April 2009. In the fiscal year to 31 December 2025, it reported revenue of SEK 17.5m and a net loss of SEK 41.6m. At that date it held total assets of SEK 76.5m and shareholders' equity of SEK 69.7m.
Clinical Laserthermia Systems AB engages in the development and manufacture of pharmaceutical products. The company is headquartered in Lund, Skane. The company went IPO on 2009-04-16. The firm develops and markets a product for the treatment of solid cancer tumors. The product is based on Immunostimulating Laser Thermo Therapy (imILT). imILT method can be used for all tumors in solid organ and the potential market is considerable. Examples of tumors which are suitable for treatment are those found in liver, breast, lung, prostate, kidney, pancreas and thyroid. Clinical Laserthermia Systems AB's treatment system consists of two main parts: a mobile laser device and a sterile patient unit for single use. The firm's product is intended for medical professionals within surgical oncology or interventional radiology within oncology. In April 2014, the Company announced the establishment of a subsidiary in the United States.
Figures and description from our data supplier, not checked against the company's own report.
Company facts
- Sector
- Health Care
- Industry
- Health Care Equipment & Supplies
- Listed since
- 16 Apr 2009
- Employees
- 6
- Website
- clinicallaser.se ↗
Leadership
Pay as last reported
- Mr. Peter MaxChairman of the Board, since 2024
- Mr. Dan MogrenChief Executive Officer, since 2022
- Mr. Hakan RosqvistInterim Chief Financial Officer
- Mr. Michael MagnaniManaging Director of CLA Americas Inc.
- Mr. Jimmy JohanssonExecutive Vice President - Operations
- Mr. Stephan DymlingChief Technology Officer
- Lotta LjungbergVice President - Regulatory Affairs & Quality Assurance
- Mr. Kristian WaldeckVice President - Medical Affairs
- Dr. Stefan AstromHead of Clinical Development
- Mr. Mats EkelundChief Medical Officer
- Mr. Ingmar MalmDirector of Quality Assurance
- Ms. Karin PetersonChief Product Officer
Environmental, social and governance
Scores out of 100, from our data supplier
- Overall
- 0
- Environment
- 0
- Social
- 0
- Governance
- 0
SWOT analysis
AI-generated by our data supplier. Not written or checked by our editors.
Strengths
- Develops innovative imILT technology for solid cancer tumor treatment.
- Mobile laser device and sterile patient unit for single-use medical applications.
- Subsidiary established in the United States for market expansion.
Weaknesses
- Only 6 full-time employees limit operational capacity.
- IPO on 16 April 2009 indicates limited market history.
- Headquartered in Lund, Skane, Sweden, restricting local market access.
Opportunities
- Potential market for imILT treatment in liver, breast, lung, prostate, kidney, pancreas, and thyroid tumors.
- Expanding into surgical oncology and interventional radiology sectors.
- Growing demand for innovative cancer treatments globally.
Threats
- Competition from established cancer treatment methods in the Health Care sector.
- Regulatory challenges in the Health Care industry for new medical devices.
- Limited resources compared to larger pharmaceutical companies.
Sources and methodology
- Data on this tab
- Our data supplier
- Chart on the Overview
- TradingView
Nothing here is investment advice. Prices can be delayed or wrong, so check with the exchange before relying on them. Data for this page. How we cover markets.